Search

Your search keyword '"Nicola Fossati"' showing total 32 results
Start Over Author "Nicola Fossati" Journal european urology supplements
32 results on '"Nicola Fossati"'

1. The prognostic significance of persistently elevated PSA after radical prostatectomy is highly associated with pathological stage: Implications for timely use of salvage treatments

Author

Umberto Capitanio, Renzo Colombo, Vincenzo Mirone, Giorgio Gandaglia, Stephen A. Boorjian, Alberto Briganti, R. Jeffrey Karnes, William Parker, Emanuele Zaffuto, Carlo Andrea Bravi, Manuela Tutolo, Marco Bandini, Nicola Fossati, Nazareno Suardi, and Francesco Montorsi

Subjects
medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine, Stage (cooking), business, Elevated PSA, Pathological
Published
2018

2. Robot-assisted partial nephrectomy for complex cases (Padua score ≥ 10): Results from a multicenter experience at three high-volume centers

Author

Paolo Casale, Alessandro Larcher, Alexandre Mottrie, Davide Maffei, Massimo Lazzeri, Giovanni Forni, James R. Porter, G.F. Guazzoni, Nicolò Maria Buffi, Giovanni Lughezzani, Giuliana Lista, Rodolfo Hurle, Alberto Saita, and Nicola Fossati

Subjects
medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, medicine, business, Nephrectomy, Surgery, Volume (compression)
Published
2017

3. Assessing the 20-year outcomes of radical prostatectomy for high risk prostate cancer: Results from a large, multi-institutional series

Author

Paolo Gontero, Francesco Montorsi, R. Jeffrey Karnes, Paolo Dell'Oglio, Giorgio Gandaglia, Nazareno Suardi, Martin Spahn, Nicola Fossati, Stefania Munegato, Steven Joniau, Marco Bandini, Armando Stabile, Michele Colicchia, Marco Bianchi, and Alberto Briganti

Subjects
Oncology, medicine.medical_specialty, Series (stratigraphy), Prostate cancer, business.industry, Prostatectomy, Urology, Internal medicine, medicine.medical_treatment, medicine, medicine.disease, business
Published
2017

4. Are the results of the ProtecT trial applicable to contemporary prostate cancer patients treated at two high-volume European Institutions?

Author

Emanuele Zaffuto, Patrizio Rigatti, Derya Tilki, Francesco Montorsi, Markus Graefen, Paolo Dell'Oglio, Giorgio Gandaglia, Nazareno Suardi, Nicola Fossati, Alberto Briganti, Raisa S. Pompe, and Vito Cucchiara

Subjects
Oncology, Gynecology, medicine.medical_specialty, Prostate cancer, business.industry, Urology, Internal medicine, medicine, business, medicine.disease, Volume (compression)
Published
2017

5. Development and split-sample validation of the first nomogram to identify the candidates for extended pelvic lymph node dissection among men staged with multi-parametric MRI for clinically localized prostate cancer

Author

Giorgio Gandaglia, Paolo Dell'Oglio, Nicola Fossati, Alexandre de la Taille, Antonio Esposito, Francesco De Cobelli, Shahrokh F. Shariat, Francesco Montorsi, Laurent Salomon, Pietro Grande, Matteo Soligo, Raphaële Renard-Penna, Alberto Briganti, Giorgio Brembilla, Morgan Rouprêt, Jeffrey Karnes, Bernhard Grubmüller, Giulia Cristel, and Armando Stabile

Subjects
medicine.medical_specialty, Multi parametric, business.industry, Urology, Dissection (medical), Nomogram, medicine.disease, Prostate cancer, medicine.anatomical_structure, Split sample, medicine, Radiology, business, Lymph node
Published
2018

6. Assessing the 20-year outcomes of lymph node positive prostate cancer patients: A plea for lifelong follow-up

Author

Emanuele Zaffuto, Carlo Andrea Bravi, Matteo Soligo, Alberto Briganti, Giorgio Gandaglia, Felix Preisser, Markus Graefen, Marco Bandini, Derya Tilki, Jeffrey Karnes, Francesco Montorsi, Fabio Muttin, Pierre I. Karakiewicz, Paolo Dell'Oglio, Elio Mazzone, and Nicola Fossati

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, Plea, Lymph node positive, business.industry, Urology, Internal medicine, medicine, business, medicine.disease
Published
2018

7. Association between rs6152 polymorphism in the androgen receptor gene and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy

Author

Dejan Lazarevic, Marco Bianchi, Alberto Briganti, Francesco Montorsi, Shahrokh F. Shariat, Giovanni Tonon, Rodolfo Montironi, Vincenzo Mirone, Nicola Fossati, Matteo Zoccolillo, Giorgio Gandaglia, Vito Cucchiara, and Davide Cittaro

Subjects
Oncology, medicine.medical_specialty, Prostatectomy, business.industry, Androgen Receptor Gene, Urology, medicine.medical_treatment, Disease, medicine.disease, Prostate cancer, Internal medicine, medicine, business, Prospective cohort study
Published
2018

8. Single nucleotide polymorphisms and risk of prostate cancer: Development and validation of a novel genetic risk score for individualized screening and diagnostic programmes

Author

Giorgio Gandaglia, Marco Bianchi, Vincenzo Mirone, Alberto Briganti, Matteo Zoccolillo, Nicola Fossati, Shahrokh F. Shariat, Vito Cucchiara, Francesco Montorsi, Dejan Lazarevic, Davide Cittaro, and Giovanni Tonon

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, business.industry, Urology, Internal medicine, medicine, Single-nucleotide polymorphism, Genetic risk, business, medicine.disease
Published
2018

9. Stage-migration and survival of lymph node positive prostate cancer patients: A comprehensive trend analyses of surgically treated men over the last two decades

Author

Rodolfo Montironi, Pierre I. Karakiewicz, Armando Stabile, Francesco Montorsi, Carlo Andrea Bravi, Felix Preisser, Matteo Soligo, Marco Bianchi, Emanuele Zaffuto, Nicola Fossati, Alberto Briganti, Shahrokh F. Shariat, Giorgio Gandaglia, Derya Tilki, Jeffrey Karnes, Markus Graefen, Marco Bandini, Paolo Dell'Oglio, and Elio Mazzone

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, Lymph node positive, business.industry, Urology, Internal medicine, medicine, medicine.disease, business, Stage migration
Published
2018

10. Impact of variant histologic differentiation in bladder cancer patients on recurrence pattern after radical cystectomy: Implications for follow up schemes

Author

Giorgio Gandaglia, Agostino Mattei, Nicola Fossati, Marco Bianchi, Marco Moschini, Alberto Briganti, Andrea Salonia, Federico Dehò, Rocco Damiano, Andrea Gallina, Nazareno Suardi, Giusy Burgio, Renzo Colombo, and Francesco Montorsi

Subjects
Cystectomy, medicine.medical_specialty, Bladder cancer, business.industry, Urology, medicine.medical_treatment, medicine, business, medicine.disease
Published
2018

11. Which patients with low-risk prostate cancer are still receiving radical prostatectomy? Impact of patient selection on inverse stage migration at two European, tertiary referral centers

Author

Marco Bianchi, Alberto Briganti, Francesco Cianflone, Emanuele Zaffuto, Nicola Fossati, Francesco Montorsi, Federico Dehò, Rocco Damiano, Markus Graefen, Armando Stabile, Marco Bandini, Firas Abdollah, Andrea Gallina, Elio Mazzone, Felix Preisser, Pierre I. Karakiewicz, Paolo Dell'Oglio, Giorgio Gandaglia, and Derya Tilki

Subjects
Oncology, medicine.medical_specialty, Referral, Prostatectomy, business.industry, Urology, medicine.medical_treatment, medicine.disease, Stage migration, Prostate cancer, Internal medicine, medicine, business, Selection (genetic algorithm)
Published
2018

12. Prevalence and prognostic impact of prostate cancer histological variants at radical prostatectomy: A long-term, single center analysis

Author

Giorgio Gandaglia, Massimo Freschi, Nicola Fossati, Rodolfo Montironi, Roberto Bertini, Claudio Doglioni, Andrea Gallina, Alberto Briganti, Francesco Montorsi, Roberta Lucianò, Carlo Andrea Bravi, Vincenzo Scattoni, Pierre I. Karakiewicz, Vincenzo Mirone, Emanuele Zaffuto, and Shahrokh F. Shariat

Subjects
Oncology, Prostate cancer, medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, Internal medicine, Medicine, business, medicine.disease, Single Center, Term (time)
Published
2018

15. 430 Patterns of clinical recurrence and predictors of systemic progression of prostate cancer patients with PSA persistence after radical prostatectomy

Author

Paolo Dell'Oglio, Marco Bianchi, Marta Picozzi, Alberto Briganti, Vito Cucchiara, Francesco Montorsi, E. Farina, Nicola Fossati, Roberto Bertini, Giorgio Gandaglia, Rocco Damiano, and Federico Dehò

Subjects
Oncology, Persistence (psychology), medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine.disease, Prostate cancer, Internal medicine, Clinical recurrence, medicine, business
Published
2016

16. 431 External validation of a model predicting survival of men with recurrent prostate cancer after radical prostatectomy

Author

Paolo Dell'Oglio, Zhe Tian, Nazareno Suardi, Nicola Fossati, Umberto Capitanio, Jeffrey Karnes, Marco Moschini, Pierre I. Karakiewicz, Stephen A. Boorjian, Alberto Briganti, Giorgio Gandaglia, and Francesco Montorsi

Subjects
Oncology, medicine.medical_specialty, business.industry, Prostatectomy, Urology, Internal medicine, medicine.medical_treatment, medicine, External validation, Recurrent prostate cancer, business
Published
2016

17. 170 Hypogonadism independently predicts pathological Gleason pattern 5 at the time of radical prostatectomy

Author

Marco Moschini, Nicola Fossati, Alessandro Larcher, Guido Barbagli, Shahrokh F. Shariat, Eugenio Ventimiglia, Giorgio Gandaglia, Renaud Bollens, Armando Stabile, Giuseppe Saitta, Paolo Dell'Oglio, Alberto Briganti, and Francesco Montorsi

Subjects
Gleason pattern, medicine.medical_specialty, Prostatectomy, business.industry, Urology, medicine.medical_treatment, medicine, business, Pathological
Published
2016

18. 1012 Long-term outcomes of patients with seminal vesicle invasion at radical prostatectomy: The importance of a multi-modal approach to increase patient survival

Author

Marco Bianchi, Alberto Briganti, R. Jeffrey Karnes, Marco Moschini, Francesco Montorsi, Firas Abdollah, Nicola Fossati, Nazareno Suardi, Emanuele Zaffuto, Alessandro Larcher, Giorgio Gandaglia, and Cesare Cozzarini

Subjects
medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, Long term outcomes, Medicine, Patient survival, Multimodal therapy, business, Seminal vesicle invasion
Published
2015

19. 624 Functional outcomes after robot-assisted radical prostatectomy in young patients (≤ 55 yrs) with prostate cancer: Is surgery perfect in the best candidates?

Author

Giovanni Lughezzani, Alberto Briganti, Nicola Fossati, N. Suardi, Alessandro Larcher, G.F. Guazzoni, Nicolò Maria Buffi, Massimo Lazzeri, Paolo Dell'Oglio, Giuliana Lista, and F. Montorsi

Subjects
Prostate cancer, medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine, medicine.disease, business
Published
2015

20. 938 When should a positive surgical margin (SM) ring a bell? An analysis of a multi-institutional Robotic-Assisted Laparoscopic radical Prostatectomy (RALP) database

Author

Daniel Pucheril, M. Menon, Andrea Gallina, M. Graefen, C. Rogers, Alberto Briganti, Nicola Fossati, F. Montorsi, Akshay Sood, Burkhard Beyer, Jesse D. Sammon, James O. Peabody, Alexander Haese, Hans Stricker, G. Gandaglia, Firas Abdollah, and Dane E. Klett

Subjects
Ring (mathematics), medicine.medical_specialty, Laparoscopic radical prostatectomy, business.industry, Robotic assisted, Urology, medicine.medical_treatment, medicine, Positive Surgical Margin, business, Surgery
Published
2015

21. 191 Cancer-control outcomes in patients with clinically high-risk prostate cancer (PCa) treated with robotic-assisted laparoscopic radical prostatectomy (RALP): A multi-institutional database analysis

Author

Dane E. Klett, Mani Menon, Akshay Sood, Firas Abdollah, Jesse D. Sammon, Nicola Fossati, Hans Stricker, Markus Graefen, Francesco Montorsi, Craig G. Rogers, James O. Peabody, Alberto Briganti, Alexander Haese, Burkhard Beyer, Daniel Pucheril, Wooju Jeong, and Giorgio Gandaglia

Subjects
Oncology, medicine.medical_specialty, Laparoscopic radical prostatectomy, business.industry, Prostatectomy, Urology, medicine.medical_treatment, Guideline, medicine.disease, Prostate cancer, Dissection, medicine.anatomical_structure, Internal medicine, Cohort, medicine, Number needed to treat, business, Lymph node
Abstract

INTRODUCTION AND OBJECTIVES: Contemporary adherence to European Association of Urology (EAU) guideline recommendation for pelvic lymph node dissection (PLND) at either open (ORP) or robot-assisted radical prostatectomy (RARP) in an European high-volume center is unknown. To assess guideline recommended and observed PLND rates at ORP or RARP in a high-volume center cohort. METHODS: We relied on a large European institutional database and focused on localized prostate cancer (PCa) patients, who were treated with either ORP or RARP, between 2010 and 2013. Categorical and multivariable logistic regression analyses targeted two endpoints: 1) probability of guideline recommended PLND and 2) probability of no PLND, when not recommended by EAU guidelines. RESULTS: Within 7,868 PCa patients, adherence to EAU PLND guideline recommendation was 97.1% at ORP and 96.8% at RARP. When PLND was not recommended, it was more frequently performed at RARP (71.6%) than at ORP (66.2%). At recommended PLND, 21.1% of ORP patients harbored lymph node invasion (LNI) (number needed to treat (NNT): 4.7) vs. 9.9% RARP (NNT: 10.1). At not recommended PLND, 2.9% of ORP patients harbored LNI (NNT: 34.5) vs. 1.4% in RARP (NNT: 71.4). CONCLUSIONS: Adherence to EAU guideline recommended PLND is high at this high-volume center. Neither ORP nor RARP represent a barrier for PLND, when recommended. However, a high number of patients underwent PLND despite absence of guideline recommendation. Possible staging advantages and PLND related complications needs to be individually considered, especially, when LNI risk is low.

Published
2015

22. 924 Predicting perioperative outcomes of robot assisted partial nephrectomy: The role of hospital case volume in the early phase of adoption

Author

Rajesh Ahlawat, D. Moon, Francesco Porpiglia, Alexandre Mottrie, Alessandro Larcher, Deepansh Dalela, Nicolò Maria Buffi, Nicola Fossati, Ronney Abaza, Sudhir Rawal, A. Volpe, Craig G. Rogers, G. Novara, and Ben Challacombe

Subjects
medicine.medical_specialty, Case volume, business.industry, Urology, medicine.medical_treatment, medicine, Perioperative, Early phase, business, Nephrectomy, Surgery
Published
2015

23. 452 Updated postoperative nomogram incorporating the number of positive lymph nodes to predict disease recurrence following radical prostatectomy

Author

Nicola Fossati, Karim Touijer, Andrew J. Vickers, Renato B. Corradi, Antoni Vilaseca, Peter T. Scardino, Daniel Nguyen, Michael S. Kent, Daniel Sjöberg, James A. Eastham, and Nicole Benfante

Subjects
medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, Medicine, Lymph, Disease, Nomogram, business
Published
2015

24. 905 Predicting lymph node invasion in contemporary North-American patients treated with robot-assisted radical prostatectomy

Author

M. Graefen, Daniel Pucheril, Alberto Briganti, Hans Stricker, Akshay Sood, N. Suardi, Mireya Diaz, F. Montorsi, James O. Peabody, Burkhard Beyer, M. Menon, G. Gandaglia, Firas Abdollah, Jesse D. Sammon, Nicola Fossati, and Dane E. Klett

Subjects
medicine.medical_specialty, medicine.anatomical_structure, business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine, Radiology, business, Lymph node
Published
2015

25. 1041 Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for selection of active surveillance candidates

Author

Marco Bianchi, Alberto Briganti, Nicola Fossati, Emanuele Zaffuto, Umberto Capitanio, Shahrokh F. Shariat, Giuseppe Zanni, Giorgio Gandaglia, Firas Abdollah, Federico Dehò, Francesco Montorsi, Nazareno Suardi, and Pierre I. Karakiewicz

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, business.industry, Urology, Internal medicine, medicine, Identification (biology), Disease, medicine.disease, business, Intermediate risk, Selection (genetic algorithm)
Published
2015

26. 1031 Population-based comparison of cancer specific mortality after local tumor ablation or nonactive treatment for T1a kidney cancer: A competing risk analysis

Author

Zhe Tian, Nicolò Maria Buffi, Maxine Sun, P.I. Karakiewicz, V. Trudeau, Alessandro Larcher, K. Böhm, G.F. Guazzoni, M. Meskawi, Nicola Fossati, Giovanni Lughezzani, and R. Valdivieso

Subjects
Oncology, medicine.medical_specialty, business.industry, Urology, Cancer, urologic and male genital diseases, medicine.disease, Renal neoplasm, Metastasis, Renal cell carcinoma, Internal medicine, medicine, Resection margin, Oncocytic Neoplasm, Oncocytoma, Radiology, business, Kidney cancer
Abstract

INTRODUCTION AND OBJECTIVES: Oncocytomas are benign renal tumors with minimal malignant potential. However, the natural history of indeterminate tumors with oncocytic features such as “oncocytic neoplasm” and “renal cell carcinoma unclassified with oncocytic features” (RCC unclassified) is less clearly understood. Our aim was to compare the oncologic outcomes in oncocytic tumors to those seen in pure oncocytoma to determine their aggressive potential. METHODS: Pathology reports for all partial and radical nephrectomies performed at our institution from 1999 through 2014 were reviewed. Reports with the term oncocytoma, “oncocytic neoplasm,” “oncocytosis,” and “renal cell carcinoma unclassified with oncocytic features” were included in the study. Concurrent renal neoplasms of other histologic subtype (clear cell, papillary, urothelial) and tumors secondary to known hereditary syndrome were excluded. Descriptive statistics were used to compare patients with oncocytic variant tumors to those with pure oncocytoma. RESULTS: Ninety-five patients were included in the study (70 oncocytoma, 6 oncocytic neoplasm, and 19 RCC unclassified). Median overall follow-up time was 31 months (IQR 7 e 69). Follow-up time per cohort was 34 months (IQR 6 e 71) for oncocytoma, 40 (IQR 15 e 77) for oncocytic neoplasms, and 16.5 (IQR 6 e 38) for RCC unclassified. Demographic characteristics (age, sex, race) were similar between the three groups. The majority of tumors in all groups were discovered incidentally. Mean (SD in cm) tumor size was 3.8 cm (2.4) in pure oncocytomas, 2.3 cm (0.9) in oncocytic neoplasms, and 4.5 cm (3.4) in RCC unclassified tumors (p 1⁄4 0.232). Eight patients had cancer at the resection margin, and all were pure oncocytoma (p 1⁄4 0.327). In comparing oncologic outcomes, there were no significant differences between the groups. No patients experienced local recurrence or metastasis. One patient with oncocytoma (1%) and 2 patients with RCC unclassified (11%) died during follow-up (p 1⁄4 0.168). No deaths were related to their renal tumors. CONCLUSIONS: Although representing a small cohort, the data here provide evidence that variant tumors with oncocytic features behave more like oncocytoma than renal cell carcinoma. Surgery appears to be curative and should steer urologists towards a less aggressive post-operative surveillance pathway whenever possible.

Published
2015

27. 1017 Systematic assessment of positive surgical margins features in open vs. robot-assisted radical prostatectomy: Is there a difference?

Author

Massimo Freschi, Marco Bianchi, Stefano Luzzago, Alberto Briganti, Giorgio Gandaglia, Shahrokh F. Shariat, Umberto Capitanio, Francesco Montorsi, Nicola Fossati, Nazareno Suardi, Paolo Dell'Oglio, Pierre I. Karakiewicz, and Walter Cazzaniga

Subjects
medicine.medical_specialty, Prostatectomy, business.industry, Urology, General surgery, medicine.medical_treatment, medicine, Positive Surgical Margin, business
Published
2015

28. 1016 Long-term clinical recurrence (CR) rate in prostate cancer (PCa) patients with adverse pathological characteristics at robotic-assisted laparoscopic radical prostatectomy (RALP)

Author

C. Rogers, B. Burkhard, G. Gandaglia, Jesse D. Sammon, Firas Abdollah, Markus Graefen, Daniel Pucheril, Akshay Sood, Alberto Briganti, Nicola Fossati, N. Suardi, James O. Peabody, F. Montorsi, Alexander Haese, Dane E. Klett, and M. Menon

Subjects
medicine.medical_specialty, Prostate cancer, Laparoscopic radical prostatectomy, Robotic assisted, business.industry, Urology, Clinical recurrence, medicine.medical_treatment, medicine, medicine.disease, business, Pathological
Published
2015

29. 352 Prostate health index predicts biochemical recurrence in patients with organ-confined prostate cancer treated with radical prostatectomy

Author

Giulio Maria Gadda, Alessandro Larcher, Giovanni Lughezzani, Massimo Lazzeri, Alessandro Mistretta, Nicola Fossati, Paolo Dell'Oglio, Alberto Abrate, G.F. Guazzoni, Giuliana Lista, Nicolò Maria Buffi, and Ella Kinzikeeva

Subjects
Oncology, Biochemical recurrence, medicine.medical_specialty, business.industry, Prostatectomy, Urology, medicine.medical_treatment, medicine.disease, Health index, Prostate cancer, medicine.anatomical_structure, Prostate, Internal medicine, medicine, In patient, business
Published
2014

32. 1010 ASSESSING THE RISK OF LYMPH NODE INVASION IN PATIENTS WITH INTERMEDIATE RISK PROSTATE CANCER. A NOVEL PREDICTION TOOL

Author

Umberto Capitanio, Marco Bianchi, Nazareno Suardi, Roberto Bertini, Andrea Gallina, Alberto Briganti, L. Villa, Patrizio Rigatti, Vincenzo Scattoni, Niccolo Passoni, Firas Abdollah, Manuela Tutolo, Nicola Fossati, and Francesco Montorsi

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, medicine.anatomical_structure, business.industry, Urology, Internal medicine, medicine, In patient, Intermediate risk, business, medicine.disease, Lymph node
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results